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Abstract
Aspergillus terreus (A. terreus) is of serious concern because of a high propensity to dissemination and in vitro and in vivo resistance to
Amphotericin B (AmB). The underlying molecular mechanism of AmB is not known yet and here we want to explore whether fungal
heat shock protein 90 (HSP90) is involved in polyene resistance in A. terreus. AmB-susceptible (ATS) and AmB-resistant (ATR) A. terreus
and AmB-susceptible Aspergillus fumigatus (AFS) were investigated in response to AmB with a special focus on HSP90. HSP90 inhibitors
resulted in signiﬁcant improvement of AmB activity against ATR as minimum inhibitory concentrations (MIC) decreased from 32 to
0.38 mg/L. Gene expression proﬁling showed a greater basal amount of HSP90 levels in ATR and ATS when compared with AFS.
HSP90 blockers in combination with AmB were evaluated in a murine model of disseminated aspergillosis. HSP90 inhibitors were not
beneﬁcial for mice infected with ATR, and neither mono- nor combination treatment with AmB yielded clinical improvement. HSP90
inhibition with 17-allylamino-17-demethoxygeldanamycin (17-AAG) was harmful. HSP90 seems to play a vital role in antifungal stress
response in all aspergilli tested, whereas HSP90 does not substantiate the origin of AmB resistance in ATR.
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Introduction
Invasive fungal infections (IFIs) are an important cause of
morbidity and mortality in patients with underlying risk fac-
tors (e.g. neutropenia, cancer chemotherapy or AIDS) [1,2].
There are a wide variety of pathogens associated with IFIs,
yet the predominant players are Candida and Aspergillus spe-
cies [3]. The most frequently isolated mould from clinical
specimens is Aspergillus fumigatus, but Aspergillus terreus
appears to be an emerging cause of infection at some institu-
tions (e.g. the Medical University Hospital of Innsbruck, Aus-
tria, and the M. D. Anderson Cancer Center in Houston,
Texas, USA) [4,5] and an endemic appearance of A. terreus is
shown [6]. A. terreus infections are of serious concern
because most isolates exhibit in vivo and in vitro resistance
(MIC ‡2 mg/L) to Amphotericin B (AmB) [7,8]. The reason
for this resistance is not known yet and the exact mode of
AmB action is still incompletely understood [9–11]. Recent
studies identiﬁed HSP90 as a regulator for emergence of fun-
gal drug resistance of two leading fungal pathogens, Candida
albicans and A. fumigatus [12,13]. The molecular chaperone
HSP90 assists in protein folding, cell signalling, and tumour
repression. HSP90 is one of the most represented proteins
in the cytosol of eukaryotes as it makes up 1–2% of the
complete protein level, also without the inﬂuence of stress.
Cellular stress can be induced by nutrient deprivation, chan-
ged temperature or pH and exposure to various toxins and
drugs [14,15]. Another study demonstrated that Mycograb,
a single-chain variable fragment genetically recombinant
monoclonal antibody, which acts against the fungal molecular
chaperone HSP90, increased AmB efﬁcacy in vivo [16].
Biamonte et al. [17] showed that pharmacological HSP90
inhibition leads to a degradation of oncogenic proteins and
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that HSP90 inhibitors can be used in the treatment of a
wide range of diseases [15,17,18], including fungal [12,14,19]
and parasitic pathogens [20], both in humans and animals.
In light of these observations, we investigated the in vivo
and in vitro role of HSP90 in polyene resistance in A. terreus.
Materials and Methods
Fungal strains
All Aspergillus spp. isolates (species identiﬁcation via sequenc-
ing of ITS3-ITS4, calmodulin, b-tubulin, enolase and cyto-
chrom B) used in this study were derived from clinical
specimens. AFS showed AmB MIC of £1.0 mg/L, ATS of
£0.5 mg/L and ATR of ‡32 mg/L.
Susceptibility testing
AmB MIC were determined by Etest (AB BIODISC, Vienna,
Austria) on deﬁned agar plates (RPMI-1640 + MOPS + 2% glu-
cose + 1.5% Agar granulated) performed according to the man-
ufacturer‘s instructions with an inoculum of 1–4 · 106 colony
forming units (CFU) per mL. HSP90 was blocked with geldana-
mycin (InVivoGen, Nottingham, UK), 17-AAG (Sigma, Vienna,
Austria), tacrolimus FK506 (Sigma) and cyclosporin A (Sandim-
mun, Novartis, Vienna, Austria). Preparation of each blocking
solution was carried out according to the manufacturer‘s rec-
ommendations and added to the chilled RPMI agar. For each
substance concentrations of 5, 10 and 20 lM were used.
HSP90 gene expression by northern blotting
To observe the fungal HSP90 biology we determined gene
expression of HSP90 in ATR, ATS and AFS. Conidial suspen-
sions (ﬁnal range of 1 · 105 CFU/mL) were grown in Sabou-
raud medium (Merck, Vienna, Austria) for 24 h (37C) with
slight shaking and fungi were treated with AmB (Bristol-Myers
Squibb, Vienna, Austria) at sub-lethal (S) and lethal (L) concen-
trations for 15 min. S and L concentrations were 2 mg/L (S) and
5 mg/L (L) and 0.1 mg/L (S) and 1 mg/L (L) for ATR and ATS,
and 0.25 mg/L (S) and 1 mg/L (L) for AFS, respectively. North-
ern blotting was carried out according to a previous protocol
[21]. Hybridization probes were generated by PCR using oligo-
nucleotides for the HSP90 gene 5¢-TCATGATACGCTC-
CATGTTG-3¢—forward and 5¢-GAGGAGCTCAACAAGA
CCAA-3¢—reverse for A. terreus and 5¢-CAT CTC CTA CCC
CAT CTA CC-3¢—forward and 5¢-CTG TCA AGG AAG GGA
GAC TT-3¢—reverse for A. fumigatus.
HSP90 gene expression by real-time PCR
Isolates (1 · 105 CFU/mL, 24 h at 37C with slight shaking)
were treated with sub-lethal and lethal AmB concentrations
for 15 min. RNA was isolated by use of TRI reagent (Sigma)
[21]. For cDNA preparation 4 lg of RNA were transcribed
using the Superscript-III-RT-Kit (Invitrogen, Vienna, Austria).
Real-time PCR experiments were performed on a Light-Cycler
2.0 (Roche) via Light-Cycler Software 4.1. SensiMixLite-Kit
(Quantace, London, UK) was used for all reactions. Each real-
time PCR was carried out in 20-lL glass capillaries (Roche,
Vienna, Austria) containing 4 lL SensiMix Lite, 1.5 lL Enzyme
Mix, 0.4 lL 50· SYBR Green I solution, 0.8 lL of each corre-
sponding primer (10 lM), 7.5 lL PCR grade water and 5 lL
cDNA (80 ng). A. terreus primers were designed using HSP90
(GenBank accession no. XM_001216617) and beta-tubulin
(BTU) (GenBank accession no. NT_165972) genes. For
A. fumigatus HSP90 (GenBank accession no. XM_742833) and
beta-tubulin (BTU) (GenBank accession no. AY048754) genes
were used. Relative expression was evaluated as previously
described [22]. The ratio of the target gene is expressed vs.
the control in comparison with the reference gene.
In vivo combination of AmB and HSP90 blocker
The in vivo effect of AmB treatment in combination with
HSP90 blockers was investigated with a murine model
including 54 female BALB/c-mice (groups A to I; six mice per
group; weight 23–28 g; age 14–16 weeks). Mice in groups A-
H received intravenous cyclophosphamid (200 mg/kg), mice
in group I did not receive immunosuppression. Animals in
group A to G were infected intravenously (100 lL) with
2 · 106 CFU of ATR [23]. Mice were treated daily (days 1–
5) with the corresponding therapies; group A received 2 mg/
kg/day AmB, group B 2 mg/kg/day AmB plus 20 mg/kg/day
17-AAG (less toxic geldanamycin analogue, Invivo Gen),
group C 2 mg/kg/day AmB plus 60 mg/kg/day 17-AAG, group
D 60 mg/kg/day 17-AAG, group E 2 mg/kg/day AmB plus
50 mg/kg/day cyclosporin A (Sandimmun) and group F
50 mg/kg/day cyclosporin A. Mice in group G, which were
immunosuppressed and infected daily received phosphate
buffered saline (PBS). Animals in group H (immunosup-
pressed, not infected) received PBS daily and mice in group I,
which were not immunosuppressed and not infected, did not
obtain any treatment. High and low level treatment of 17-
AAG was investigated [24]. Each substance was prepared
according to the manufacturer‘s recommendations. Mice
were observed daily and evaluated by assigning body weight
and clinical signs of infection (e.g. scrubby coat, head mis-
alignment, excessive loss of weight and banded back). On
day six, surviving animals were sacriﬁced and several organs
were removed for further analyses (histopathological analysis
and fungal burden in lungs). Animal studies were in compli-
ance/accordance with the Austrian animal protection law and
guidelines for scientiﬁc purposes.
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Quantitative Aspergillus real-time PCR of mouse lungs
ATR burden in lungs was examined by quantitative real-time
PCR assay on a Light Cycler 2.0 (Roche) using the real-time
quantitative PCR settings on Light Cycler Software Version
4.1. DNA isolation and real-time PCR were carried out as
previously described [25,26].
Statistical analyses
All in vitro assays were performed on three independent
occasions. Statistical analyses were performed using Student’s
two-tailed t-test with values of p <0.05 considered statisti-
cally signiﬁcant.
Results
In vitro combination of HSP90 blockers and AmB
AmB MIC without any HSP90 blocker was ‡32 mg/L for
ATR, and £1 mg/L for ATS and AFS. In ATR, HSP90 blocking
with geldanamycin (5 and 10 lM) decreased MIC to <1 mg/L
(Table 1). Cyclosporin A and tacrolimus FK506 also reduced
MIC in ATR, but not as strongly as geldanamycin. Similar
data were obtained in ATS and AFS. Geldanamycin analog
17-AAG, a less toxic substance used in our mouse model,
showed comparable effects to geldanamycin.
Northern blot and real-time PCR analyses of HSP90 after
AmB treatment
Gene expression proﬁling by northern blot (Fig. 1a) and real-
time PCR (Fig. 1b) analyses revealed expression of HSP90 in
ATR, ATS and AFS with different basal expression levels.
Compared with AFS, a higher amount of HSP90 was
detected in ATR and ATS. AFS showed a slight HSP90 up-
regulation after lethal and sub-lethal AmB treatment; in ATR
and ATS, HSP90 gene expression was not up-regulated after
lethal AmB treatment.
In vivo combination of HSP90 blockers and AmB
Overall, survival was signiﬁcantly better in all groups with no
17-AAG, as seen in Fig. 2 (p <0.05). Survival was 100% in
group A (AmB), group E (AmB and cyclosporin A) and group
F (cyclosporin A), as well as in control group G (ATR and
PBS), H (no infection and PBS) and I (control). Survival in
group B (AmB and 20 mg/kg 17-AAG), group C (AmB and
60 mg/kg 17-AAG) and group D (60 mg/kg 17-AAG) was
83.3%, 66.7% and 16.7%, respectively. Mice infected with
ATR showed clinical abnormalities such as scrubby coat, as
well as excessive loss of weight and head misalignment.
Quantitative PCR was applied to measure A. terreus load in
lungs (Fig. 3). Groups B and F showed the lowest fungal
CFU, whereas all other groups had comparable CFU
amounts. Fungal dissemination was identiﬁed in all ATR
infected groups via histopathological analyses (data not
shown).
Discussion
Our in vitro data showed that harnessing HSP90 function
increased AmB activity in A. terreus. Cowen et al. [12,13]
demonstrated that HSP90 plays an important role in antifun-
gal drug resistance. Compromising HSP90 function in C. albi-
cans reduces resistance to azoles and blocks de novo
emergence of resistance. The same effects were also noticed
in A. fumigatus for echinocandin resistance. Cowen et al.
[13,27] also showed that blocking the HSP90 client protein
calcineurin with cyclosporin A and FK506 reduced fungal
drug resistance. The immunosuppressant geldanamycin is
now in clinical development as an anticancer agent and it
binds directly to the ATP-binding pocket of HSP90, thus
altering its function [18]. In our study, geldanamycin
decreased AMB MIC of ATR from >32 mg/L to <1 mg/L.
Similar, yet slightly reduced, effects were observed for cyclo-
sporin A and FK506 in ATR, ATS and AFS. Northern blot-
ting demonstrated an approximately equal basal amount of
HSP90 gene expression in ATR and ATS. No signiﬁcant up-
regulation in response to AmB in comparison to untreated
controls was detected in both isolates. This higher basal
HSP90 equipment in A. terreus makes this species probably
more stable against different environmental and other exoge-
nous stress exposures. Thus, northern blotting and real-time
PCR showed marginal up-regulation of equal genes in AFS,
TABLE 1. In vitro effects of various HSP90 blockers on
Amphotericin B efﬁcacy
HSP90 blockers










No blocker (control) >32 0.25 1.0
Geldanamycin (5 lM) 0.75 0.125 0.19
Geldanamycin (10 lM) 0.38 0.003 0.125
Geldanamycin (20 lM) No growth No growth No growth
17-AAG (5 lM) 1.0 0.125 0.19
17-AAG (10 lM) 0.5 0.008 0.19
17-AAG (20 lM) No growth No growth No growth
Cyclosporin A (5 lM) 3.00 0.19 0.19
Cyclosporin A (10 lM) 1.00 0.125 0.19
Cyclosporin A (20 lM) 0.5 0.047 No growth
FK506 (5 lM) 4.00 0.125 0.25
FK506 (10 lM) 1.00 0.125 0.19
FK506 (20 lM) No growth No growth 0.094
Tests were performed three times in duplicates and showed similar results.
17-AAG, 17-allylamino-17-demethoxygeldanamycin.
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FIG. 1. Northern blot (a) and RT-PCR analysis (b) of HSP90 in Aspergillus spp. Incubation time was 15 min with sub-lethal (S) and lethal (L) con-
centrations of AmB. Tests were performed three times in duplicates and showed similar results. Gene expression levels of HSP90 (a) of Ampho-
tericin B-resistant (ATR) and Amphotericin B-susceptible A. terreus (ATS) were compared with susceptible A. fumigatus (AFS). Ethidiumbromide
(EtBr) staining of 26S and 18S rRNA was used as a loading control (black box). Regulation of target genes (b) in response to AmB and untreated
control was determined using crossing points (CP) in comparison to the corresponding reference gene beta-tubulin. The2DDCt relative expres-
sion ratio of the target gene HSP90 determined with the2DDCt method and fold relative expression (FRE) are shown.
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FIG. 2. Kaplan–Meier survival curve of mice
infected with 2 · 106 CFU of ATR/mouse.
Mice were treated from days 1 to 5 and sacri-
ﬁced on day 6 post-challenge. All regimes
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Treatment group
F G H I
9
A  AmB
B  AmB plus 17-AAG (20 mg)
C  AmB plus 17-AAG (60 mg)
D  17-AAG (60 mg)
E  AmB plus cyclosporin A (50 mg)
F  Cyclosporin A (50 mg)
G  PBS
H  No infection plus PBS
I   No infection plus no treatment
FIG. 3.Quantitative A. terreus real-time PCR
of mouse lungs. BALB/c-mice received immu-
nosuppression to assure fungal dissemination
and were infected intravenously with 2 · 106
conidia of ATR.
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illustrating stress interaction emanating from the exposure
to AmB. A well-established murine model of disseminated
aspergillosis gave detailed in vivo insight into 6-day survival
and fungal tissue burden by comparing combination therapies
with AmB and HSP90 inhibitors.
Our in vitro data were not conﬁrmed in vivo as antifungal
therapy of AmB in combination with HSP90 inhibitors did
not reduce fungal burden signiﬁcantly and showed no
improvement in survival. Pathological and PCR analysis
revealed fungal growth in all infected groups and did not indi-
cate a reduction of fungal dissemination. Mice receiving AmB
plus 17-AAG (20 mg) showed reduction in fungal load, yet
the survival was lower. A signiﬁcant lower survival appeared
in those groups receiving HSP90 blockers alone or in combi-
nation with AmB, indicating that this agent might negatively
inﬂuence fungal host defence. Regarding fungal tissue burden
and mortality, HSP90 blockers alone or in combination with
AmB may be too toxic for in vivo therapy for invasive asper-
gillosis due to ATR.
In clinical practice these drugs have several side-effects
such as hepatotoxicity of geldanamycin or nephrotoxicity of
calcineurin inhibitors and in fact, these immunosuppressants
render patients to be highly susceptible to fungal infections
[28], probably reduced immune response. These major
drawbacks of direct HSP90 blocking substances explain the
worse outcome in our animal setting, although 17-AAG, a
less toxic blocker, was used. Pachl et al. [29] demonstrated
that a recombinant antibody of C. albicans HSP90 in combi-
nation with AmB improved clinical outcome. Mycograb, a
human recombinant monoclonal antibody, affects fungal
pathogens speciﬁcally and does not inﬂuence host immune
response, and in general acts in a different way to pharma-
cological inhibitors [30] tested herein. Mycograb plus lipid-
associated AmB produced signiﬁcant clinical and culture-
conﬁrmed improvement in outcome for patients with inva-
sive candidiasis. Also, in larvae of the greater wax moth
Galleria mellonella and in a murine model of disseminated
candidiasis the combination therapy with HSP90 inhibitors
and azole rescued larvae from lethal C. albicans infections
and enhanced the therapeutic efﬁcacy of azoles in vivo [16].
In comparison to our data, the reasons for such differences
in outcome are not clear in detail as HSP90 inhibitors tar-
get fungal lifeblood directly and thus deregulate fungal
stress management and increase vulnerability against drugs
decrease fungal vitality.
Our data showed that fungi treated with the highest dos-
age of HSP90 inhibitors in vitro failed to grow anymore.
However, such fungicidal in vitro effects may be overlapped in
vivo. It is known that HSPs have a dual function depending on
their intracellular or extracellular location: intracellular HSPs
have a protective function and extracellular HSPs mediate
immunological functions. In our case it is imaginable that
application of cyclophosphamid, selection of pathogenic fungi
(C. albicans vs. A. terreus), laboratory animals (BALB/c mice
vs. CD1 mice) and choice of drugs (azoles vs. AmB) inﬂu-
ence fungal progression and drug–drug interactions followed
by complexities of immune responses. Also, combination of
AmB plus 17-AAG might increase toxicity issues in our
study. It is not known yet how an extension of treatment
and further reduction of 17-AAG dosage would have posi-
tively inﬂuenced the outcome in our test animals.
In conclusion, we observed that blocking HSP90 in vitro
enhances antifungal activity of AmB against ATR, ATS and
AFS, and the basal equipment of HSP90 is higher in ATR and
ATS compared with AFS; this renders A. terreus to be proba-
bly more ‘environmentally resistant’ than AFS. At higher dos-
ages HSP90 inhibitors were fungicidal per se for all tested
isolates. In vivo, application of HSP90 inhibitors does not
improve outcome. Fungal HSP90 seems to play a central role
in stress handling, and seems not to be the speciﬁc origin of
AmB resistance in A. terreus.
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